Apixaban versus rivaroxaban anti-factor Xa crossover study in Thai patients with atrial fibrillation

Open-label trial of apixaban and rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Faculty of Medicine, Chiang Mai University. Primary endpoints: Proportion of patients with peak drug concentrations within the expected on-therapy range and Proportion of patients with trough drug concentrations within the expected on-therapy range. Planned start Oct 2026; status: not yet recruiting.